Experimental models and therapeutic approaches for HBV

[1]  J. Prieto,et al.  Modulation of regulatory T‐cell activity in combination with interleukin‐12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B , 2012, Hepatology.

[2]  M. Imamura,et al.  Severe necroinflammatory reaction caused by natural killer cell‐mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse , 2012, Hepatology.

[3]  F. Zoulim,et al.  Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. , 2012, Journal of hepatology.

[4]  P. Lampertico,et al.  Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. , 2012, Journal of hepatology.

[5]  A. Lohse,et al.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.

[6]  M. Levrero,et al.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.

[7]  T. Weiss,et al.  Hepatocyte polarization is essential for the productive entry of the hepatitis B virus , 2012, Hepatology.

[8]  M. Dandri,et al.  Chimeric mouse model of hepatitis B virus infection. , 2012, Journal of hepatology.

[9]  M. Wadman.  Chimp research under scrutiny , 2011, Nature.

[10]  M. Wadman.  Lab bred chimps despite ban , 2011, Nature.

[11]  G. Raimondo,et al.  Hepatocellular carcinoma: the point of view of the hepatitis B virus. , 2011, Carcinogenesis.

[12]  G. Hartmann,et al.  5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. , 2011, Gastroenterology.

[13]  M. Imamura,et al.  Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice. , 2011, The Journal of infectious diseases.

[14]  A. Lohse,et al.  Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. , 2011, Gastroenterology.

[15]  H. Wedemeyer.  Hepatitis D revival , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[16]  H. Azzazy,et al.  Hepatitis B virus genotyping: current methods and clinical implications. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[17]  A. Alibrandi,et al.  Replicative and Transcriptional Activities of Hepatitis B Virus in Patients Coinfected with Hepatitis B and Hepatitis Delta Viruses , 2010, Journal of Virology.

[18]  T. Roskams,et al.  Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. , 2010, Journal of hepatology.

[19]  H. Blum,et al.  Generation of Covalently Closed Circular DNA of Hepatitis B Viruses via Intracellular Recycling Is Regulated in a Virus Specific Manner , 2010, PLoS pathogens.

[20]  G. Randolph,et al.  TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. , 2010, Vaccine.

[21]  K. Simon,et al.  Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels , 2010, Hepatology.

[22]  E. Fuchs,et al.  In vivo proliferation of hepadnavirus‐infected hepatocytes induces loss of covalently closed circular DNA in mice , 2010, Hepatology.

[23]  M. Imamura,et al.  HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. , 2010, The Journal of general virology.

[24]  Ding‐Shinn Chen,et al.  Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model , 2010, Proceedings of the National Academy of Sciences.

[25]  Y. Liaw,et al.  The Natural History of Chronic HBV Infection and Geographical Differences , 2010, Antiviral therapy.

[26]  F. Chisari,et al.  Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. , 2010, The Journal of clinical investigation.

[27]  Ching-Lung Lai,et al.  Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[28]  M. Dandri,et al.  The replication cycle of hepatitis B virus. , 2010, Journal of hepatology.

[29]  M. Imamura,et al.  Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. , 2009, Journal of hepatology.

[30]  F. Zoulim,et al.  Hepatitis B virus induced hepatocellular carcinoma. , 2009, Cancer letters.

[31]  M. Levrero,et al.  Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function , 2009, Proceedings of the National Academy of Sciences.

[32]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[33]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[34]  Pratip K. Chattopadhyay,et al.  The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection , 2009, Journal of Virology.

[35]  R. Bartenschlager,et al.  Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference , 2009, Hepatology.

[36]  C. Walker,et al.  Efficacy of hepatitis B vaccine against antiviral drug‐resistant hepatitis B virus mutants in the chimpanzee model , 2009, Hepatology.

[37]  J. Prieto,et al.  Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12 , 2008, Journal of Virology.

[38]  G. Leroux-Roels,et al.  The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. , 2008, Antiviral research.

[39]  M. Sugiyama,et al.  Characteristics of hepatitis B virus genotype G coinfected with genotype H in chimeric mice carrying human hepatocytes. , 2008, Virology.

[40]  N. Warner,et al.  The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound , 2008, Hepatology.

[41]  M. Nassal.  Hepatitis B viruses: reverse transcription a different way. , 2008, Virus research.

[42]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[43]  A. Quaas,et al.  Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication , 2008, Antiviral therapy.

[44]  Y. Wen,et al.  Combination of an Antiviral Drug and Immunomodulation against Hepadnaviral Infection in the Woodchuck Model , 2007, Journal of Virology.

[45]  Aarati R. Ranade,et al.  Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice , 2007, Nature Biotechnology.

[46]  S. Schaefer,et al.  Hepatitis B virus taxonomy and hepatitis B virus genotypes. , 2007, World journal of gastroenterology.

[47]  Ding‐Shinn Chen,et al.  An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection , 2006, Proceedings of the National Academy of Sciences.

[48]  R. Purcell,et al.  The half‐life of hepatitis B virions , 2006, Hepatology.

[49]  N. Izumi,et al.  Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens , 2006, Hepatology.

[50]  M. Imamura,et al.  Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif , 2006, Antimicrobial Agents and Chemotherapy.

[51]  P. Schirmacher,et al.  Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.

[52]  M. Schnölzer,et al.  Characterization of a hepatitis B and hepatitis delta virus receptor binding site , 2006, Hepatology.

[53]  M. Levrero,et al.  Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. , 2006, Gastroenterology.

[54]  F. Chisari,et al.  Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.

[55]  T. Volz,et al.  Animal models for the study of HBV replication and its variants. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[56]  M. Imamura,et al.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus , 2005, Hepatology.

[57]  W. Delaney,et al.  Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection , 2005, Antimicrobial Agents and Chemotherapy.

[58]  R. Colonno,et al.  Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection , 2005, Journal of Virology.

[59]  T. Roskams,et al.  Morphological and biochemical characterization of a human liver in a uPA‐SCID mouse chimera , 2005, Hepatology.

[60]  F. Chisari,et al.  Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. , 2005, Virology.

[61]  P. Schürmann,et al.  Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes , 2005, Hepatology.

[62]  J. Summers,et al.  Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[63]  H. Blum,et al.  Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. , 2005, Journal of hepatology.

[64]  A. Lok.  Prevention of hepatitis B virus-related hepatocellular carcinoma. , 2004, Gastroenterology.

[65]  J. Jacob,et al.  Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. , 2004, Gastroenterology.

[66]  A. Lok,et al.  Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? , 2004, Hepatology.

[67]  F. Zoulim,et al.  A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus , 2004, Hepatology.

[68]  T. Asahara,et al.  Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.

[69]  W. Delaney,et al.  Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. , 2004, Antiviral research.

[70]  B. Tennant,et al.  Clevudine Therapy with Vaccine Inhibits Progression of Chronic Hepatitis and Delays Onset of Hepatocellular Carcinoma in Chronic Woodchuck Hepatitis Virus Infection , 2004, Antiviral therapy.

[71]  F. Chisari,et al.  MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. , 2004, The Journal of clinical investigation.

[72]  R. Purcell,et al.  Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Summers,et al.  Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  H. Blum,et al.  Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes , 2003, Hepatology.

[75]  H. Jaeschke.  Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity? , 2003, Hepatology.

[76]  S. Litwin,et al.  INAUGURAL ARTICLES: Hepatocyte turnover during resolution of a transient hepadnaviral infection , 2003 .

[77]  R. Sidwell,et al.  Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. , 2003, Antiviral research.

[78]  M. Manns,et al.  Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. , 2003, Gastroenterology.

[79]  H. Friess,et al.  Primary human hepatocytes--a valuable tool for investigation of apoptosis and hepatitis B virus infection. , 2003, Journal of hepatology.

[80]  F. Zoulim,et al.  Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model , 2003, Antimicrobial Agents and Chemotherapy.

[81]  Anton P. McCaffrey,et al.  Inhibition of hepatitis B virus in mice by RNA interference , 2003, Nature Biotechnology.

[82]  P. Schultz,et al.  Searching for Interferon-Induced Genes That Inhibit Hepatitis B Virus Replication in Transgenic Mouse Hepatocytes , 2003, Journal of Virology.

[83]  R. Purcell,et al.  CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection , 2003, Journal of Virology.

[84]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  F. Chisari,et al.  Interleukin-18 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice , 2002, Journal of Virology.

[86]  F. Chisari,et al.  Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[87]  R. Sidwell,et al.  Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. , 2002, Antiviral research.

[88]  K. Walters,et al.  Half-Life of the Duck Hepatitis B Virus Covalently Closed Circular DNA Pool In Vivo following Inhibition of Viral Replication , 2002, Journal of Virology.

[89]  K. Schlemmer,et al.  Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. , 2002, Antiviral research.

[90]  C. Gibbs,et al.  Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[91]  F. Chisari,et al.  Blocking Chemokine Responsive to γ–2/Interferon (IFN)-γ Inducible Protein and Monokine Induced by IFN-γ Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes , 2001, The Journal of experimental medicine.

[92]  L. Corey,et al.  Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. , 2001, The Journal of infectious diseases.

[93]  C. Rogler,et al.  Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation , 2001, Hepatology.

[94]  C. Gibbs,et al.  Antiviral Efficacy and Pharmacokinetics of Oral Adefovir Dipivoxil in Chronically Woodchuck Hepatitis Virus-Infected Woodchucks , 2001, Antimicrobial Agents and Chemotherapy.

[95]  D. Tyrrell,et al.  Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.

[96]  Mengji Lu,et al.  Evaluation of New Approaches to Prophylactic and Therapeutic Vaccinations against Hepatitis B Viruses in the Woodchuck Model , 2001, Intervirology.

[97]  H. Blum,et al.  Efficient Infection of Primary Tupaia Hepatocytes with Purified Human and Woolly Monkey Hepatitis B Virus , 2001, Journal of Virology.

[98]  H. Schaller,et al.  Transfer of Hepatitis B Virus Genome by Adenovirus Vectors into Cultured Cells and Mice: Crossing the Species Barrier , 2001, Journal of Virology.

[99]  C. Rogler,et al.  Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus , 2001, Hepatology.

[100]  M. Nassal,et al.  Hepatitis B Virus (HBV) Virion and Covalently Closed Circular DNA Formation in Primary Tupaia Hepatocytes and Human Hepatoma Cell Lines upon HBV Genome Transduction with Replication-Defective Adenovirus Vectors , 2001, Journal of Virology.

[101]  F. Chisari,et al.  Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo , 2000, The Journal of experimental medicine.

[102]  E. Galun,et al.  Preclinical Evaluation of Two Human Anti–Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV‐Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees , 2000, Hepatology.

[103]  V. Pasquetto,et al.  Host–Virus Interactions during Malaria Infection in Hepatitis B Virus Transgenic Mice , 2000, The Journal of experimental medicine.

[104]  H. Will,et al.  Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir In vitro do not lead to reduction of the closed circular DNA , 2000, Hepatology.

[105]  F. Chisari,et al.  Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines , 2000, Journal of Virology.

[106]  S. Locarnini,et al.  In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir , 2000, Antimicrobial Agents and Chemotherapy.

[107]  E. Galun,et al.  Reduced hepatitis B virus surface antigen–specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen‐specific antibodies in the Trimera mouse , 2000, Hepatology.

[108]  M. Shapiro,et al.  Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus , 1999, Hepatology.

[109]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[110]  E. Galun,et al.  The hepatitis B virus–trimera mouse: A model for human HBV infection and evaluation of anti‐HBV therapeutic agents , 1999, Hepatology.

[111]  F. Chisari,et al.  Hepatitis B Virus RNA-Binding Proteins Associated with Cytokine-Induced Clearance of Viral RNA from the Liver of Transgenic Mice , 1999, Journal of Virology.

[112]  I. Medina,et al.  Efficacy of the Carbocyclic 2′-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection , 1998, Antimicrobial Agents and Chemotherapy.

[113]  A Sette,et al.  Human class I supertypes and CTL repertoires extend to chimpanzees. , 1998, Journal of immunology.

[114]  H. Isom,et al.  Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus , 1998, Hepatology.

[115]  H. Erb,et al.  Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection , 1998, Hepatology.

[116]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[117]  J. Cullen,et al.  Lamivudine therapy of WHV-infected woodchucks. , 1998, Virology.

[118]  R. Rico-Hesse,et al.  Isolation of a hepadnavirus from the woolly monkey, a New World primate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[119]  R. Dwek,et al.  Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking , 1998, Nature Medicine.

[120]  C. Rogler,et al.  Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[121]  W. Mason,et al.  Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus , 1997, Journal of virology.

[122]  J. Cullen,et al.  In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks , 1997, Antimicrobial agents and chemotherapy.

[123]  F. Chisari.  Cytotoxic T cells and viral hepatitis. , 1997, The Journal of clinical investigation.

[124]  D. Miller,et al.  Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. , 1996, Virology.

[125]  F. Chisari,et al.  The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice , 1996, Journal of virology.

[126]  P. Schirmacher,et al.  Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication , 1996, Journal of virology.

[127]  H. Blum,et al.  Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo , 1996, Hepatology.

[128]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[129]  F. Chisari,et al.  High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.

[130]  S. Günther,et al.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients , 1995, Journal of virology.

[131]  S. Locarnini,et al.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes , 1995, Journal of virology.

[132]  R. Palmiter,et al.  Complete reconstitution of mouse liver with xenogeneic hepatocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[133]  W. Caselmann.  HBV and HDV replication in experimental models: effect of interferon. , 1994, Antiviral research.

[134]  H. Zentgraf,et al.  In vitro experimental infection of primary human hepatocytes with hepatitis B virus. , 1994, Gastroenterology.

[135]  F. Chisari,et al.  Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways , 1994, Journal of virology.

[136]  F. Zoulim,et al.  Woodchuck hepatitis virus X protein is required for viral infection in vivo , 1994, Journal of virology.

[137]  R. Palmiter,et al.  Replacement of diseased mouse liver by hepatic cell transplantation. , 1994, Science.

[138]  R. Anderson,et al.  The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks , 1993, Journal of virology.

[139]  C. Guguen-Guillouzo,et al.  Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. , 1993, Virology.

[140]  R. Palmiter,et al.  Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene , 1991, Cell.

[141]  A. Kakinuma,et al.  Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). , 1990, Vaccine.

[142]  R. Palmiter,et al.  Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. , 1990, Science.

[143]  Rivkina Mb,et al.  Human hepatitis B virus and hepatocellular carcinoma , 1990 .

[144]  C. Bréchot,et al.  Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide , 1988, Journal of virology.

[145]  J. Summers.  The replication cycle of hepatitis B viruses , 1988, Cancer.

[146]  M. Feitelson,et al.  A chronic carrierlike state is established in nude mice injected with cloned hepatitis B virus DNA , 1988, Journal of virology.

[147]  T. Ohmura,et al.  Properties of recombinant hepatitis B vaccine. , 1987, Biochemical and biophysical research communications.

[148]  G. Acs,et al.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[149]  J. Mullins,et al.  Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA , 1986, Cell.

[150]  G. Feldmann,et al.  Hepatitis B Vaccine Safety Monitoring in the Chimpanzee: Interpretation of Results , 1984, Journal of medical primatology.

[151]  M. Hilleman,et al.  Human hepatitis B vaccine from recombinant yeast , 1984, Nature.

[152]  H. Will,et al.  Cloned HBV DNA causes hepatitis in chimpanzees , 1982, Nature.

[153]  J. Taylor,et al.  Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[154]  F. Chisari,et al.  Transmission of type B viral hepatitis to chimpanzees. , 1973, The Journal of infectious diseases.

[155]  F. Zoulim,et al.  In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. , 2009, Gastroenterology.

[156]  F. Zoulim,et al.  Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. , 2009, The Journal of general virology.

[157]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[158]  平賀 伸彦.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2008 .

[159]  R. Yan,et al.  Human hepatitis B virus and hepatocellular carcinoma I. Experimental infection of tree shrews with hepatitis B virus , 2005, Journal of Cancer Research and Clinical Oncology.

[160]  H. Blum,et al.  The tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary tupaia hepatocytes. , 2004, Methods in molecular medicine.

[161]  G. Pape,et al.  Immunology of hepatitis B infection. , 2002, The Lancet. Infectious diseases.

[162]  F. Chisari,et al.  Noncytolytic control of viral infections by the innate and adaptive immune response. , 2001, Annual review of immunology.

[163]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.